United States Patent 9,707,181: Claim Scope, Validity Risks, and Esomeprazole-Naproxen Patent Landscape

U.S. Patent No. 9,707,181 protects a pharmaceutical unit dosage form that combines immediate or pH-independent release of esomeprazole with delayed, pH-dependent release of naproxen. The independent claim is directed to the release sequence and functional coating behavior, not merely to the presence of the two active ingredients. The dependent claims narrow the invention by specifying dose ranges, a multilayer tablet architecture, naproxen placement in the core, and conventional pharmaceutical excipients.

The claims are closely aligned with the formulation concept used in Vimovo, the fixed-dose esomeprazole magnesium and naproxen product originally developed by Pozen and commercialized by AstraZeneca. The main enforcement value lies in the combination of active ingredients, release order, and naproxen’s pH-triggered coating.

What does U.S. Patent 9,707,181 cover?

Claim 1 requires all of the following elements:

Claim element	Required scope
Dosage form	A pharmaceutical composition in unit dosage form
First active	A therapeutically effective amount of esomeprazole
Esomeprazole protection	At least part of the esomeprazole is not surrounded by an enteric coating
Second active	A therapeutically effective amount of naproxen
Naproxen protection	Naproxen is surrounded by a coating that inhibits release below pH 3.5
Esomeprazole release	At least part of the esomeprazole releases regardless of medium pH
Release sequence	Esomeprazole releases before naproxen

The claim is not limited to a particular tablet shape, manufacturing process, excipient system, or salt form of naproxen. It is also not expressly limited to a 20 mg esomeprazole and 500 mg naproxen product.

The claim uses functional language. A product may fall within the claim if its coating and release behavior satisfy the stated conditions, even if the manufacturer uses a different coating polymer, compression process, tablet geometry, or excipient system.

How broad is claim 1 of U.S. Patent 9,707,181?

Claim 1 is materially broader than the dose and multilayer-tablet claims that depend from it.

Active-ingredient combination

The claim requires both esomeprazole and naproxen in the same unit dosage form. A product containing only naproxen, only esomeprazole, or the two ingredients in separate co-packaged dosage forms would not satisfy this limitation.

The claim does not require a particular esomeprazole salt in the supplied text. Esomeprazole magnesium, esomeprazole sodium, and other pharmaceutically acceptable forms could present infringement questions depending on claim construction and the patent’s specification.

Partial non-enteric protection of esomeprazole

The phrase “at least a portion” creates a broad structural limitation. The entire esomeprazole dose does not need to be uncoated. A formulation could contain:

uncoated esomeprazole particles;
enteric-coated esomeprazole particles plus uncoated esomeprazole;
an uncoated esomeprazole layer outside an enteric-coated naproxen core; or
a mixed population of coated and uncoated esomeprazole particles.

The claim does not require that the uncoated esomeprazole be released immediately in a pharmacokinetic sense. It requires release regardless of the pH of the test medium and requires esomeprazole to release before naproxen.

Naproxen coating

The naproxen coating must inhibit release unless the dosage form is in a medium with a pH of 3.5 or higher. This limitation is directed to delayed release through a pH-dependent barrier.

The claim does not require the coating to dissolve at a particular higher pH, such as pH 5.5 or pH 6.8. A coating that begins permitting release at pH 3.5 could fall within the claim, subject to the patent’s specification and applicable claim-construction principles.

Sequential release

“Sequentially releases” is a central limitation. The claim requires esomeprazole release before naproxen release. It does not specify a minimum time interval, a percentage of drug that must be released first, or a particular dissolution apparatus in the supplied claim text.

That creates both breadth and litigation risk. The patentee would likely rely on dissolution data, release profiles, and the patent specification to establish whether a proposed product releases the two active ingredients sequentially.

What do claims 2 through 9 add?

Claim	Additional limitation	Commercial significance
2	Naproxen at 200-600 mg	Covers common 250 mg and 500 mg strengths and other amounts within the range
3	Esomeprazole at 5-100 mg	Broad range covering common 20 mg and 40 mg doses
4	Both dose ranges in the same unit dosage form	Narrower combination-dose claim
5	Multilayer tablet with a core and one or more outer layers	Targets layered tablet construction
6	Naproxen in the core layer	Narrows claim 5 to core-loaded naproxen
7	Outer layers contain no naproxen	Protects separation of naproxen from the outer esomeprazole-containing layers
8	At least one carrier	Broad excipient-related limitation
9	Specified auxiliary agents	Covers conventional lubricants, preservatives, disintegrants, stabilizers, wetting agents, buffers, colors, flavors, and related excipients

Claims 8 and 9 are unlikely to provide substantial independent protection because most pharmaceutical tablets contain one or more carriers or auxiliary agents. Their practical value is mainly as fallback claims if a narrower formulation dispute arises.

Claims 5 through 7 are more commercially important. A generic manufacturer using a multilayer tablet with naproxen in a delayed-release core and esomeprazole in an outer layer would face a more direct read-on than a manufacturer using a capsule, multiparticulate system, or physically separate tablets.

What formulations are protected by the patent?

The claims potentially cover several formulation architectures.

Multilayer tablet

A likely covered structure is:

naproxen-containing core;
pH-dependent delayed-release coating around the naproxen region;
outer layer containing uncoated esomeprazole;
optional barrier, seal, color, or protective layers.

This architecture corresponds closely to the concept of releasing esomeprazole in the stomach while delaying naproxen release until the dosage form reaches a less acidic environment.

Multiparticulate system

Claim 1 is not expressly limited to a multilayer tablet. It could potentially cover a capsule or tablet containing:

uncoated esomeprazole granules; and
enteric-coated naproxen pellets or granules.

The product would still need to satisfy the sequential-release limitation.

Coated tablet core

A single compressed tablet with a naproxen core and an outer esomeprazole-containing layer may fall within claims 1 and 5-7. The coating need not necessarily be a conventional enteric coating if it performs the claimed pH-dependent release function.

Formulations outside the likely scope

The following designs could reduce risk, depending on actual release data and claim construction:

separate naproxen and esomeprazole dosage units administered together but not contained in one unit dosage form;
a formulation in which naproxen releases before esomeprazole;
a formulation in which both active ingredients release simultaneously;
a formulation in which naproxen is not protected by a pH-dependent coating;
a formulation in which esomeprazole is fully surrounded by an enteric coating;
a formulation that releases naproxen at pH below 3.5.

A design-around based only on changing the coating polymer is less reliable because the claim is functional rather than limited to a named polymer.

How does the patent compare with Vimovo’s product design?

Vimovo combines naproxen and esomeprazole magnesium in a single modified-release tablet. The product is designed to release esomeprazole before naproxen, with naproxen delayed until the tablet reaches a less acidic environment. The FDA-approved label identifies Vimovo as a delayed-release combination product containing naproxen and esomeprazole magnesium [1].

Feature	U.S. Patent 9,707,181	Vimovo-type design
Esomeprazole	At least part not surrounded by enteric coating	Immediate-release esomeprazole component
Naproxen	Coated to inhibit release below pH 3.5	Delayed-release naproxen component
Release order	Esomeprazole before naproxen	Designed to follow this sequence
Dosage form	Any unit dosage form satisfying the claim	Tablet
Common strength	Claim 2 permits 200-600 mg naproxen	500 mg naproxen
Common esomeprazole strength	Claim 3 permits 5-100 mg	20 mg esomeprazole equivalent
Tablet architecture	Multilayer tablet covered by claims 5-7	Consistent with layered or separated-component construction

The product comparison supports a potential relationship between the patent claims and the commercial formulation, but infringement requires a product-specific analysis of composition, coating structure, and dissolution behavior.

What is the likely patent landscape for esomeprazole-naproxen combinations?

The relevant patent estate generally divides into five categories:

composition and combination patents;
multilayer-tablet and dosage-form patents;
pH-dependent naproxen coating patents;
method-of-use patents involving gastrointestinal protection; and
manufacturing and process patents.

The broadest commercial risk usually comes from claims that combine formulation structure with release behavior. A patent limited to a specific coating polymer may be easier to design around than a claim requiring release below or above a defined pH.

Relevant patent categories

Patent category	Typical protected subject matter	Risk to an ANDA applicant
Combination composition	Esomeprazole plus naproxen in one unit	High if the product uses the same actives
Release sequence	Esomeprazole before naproxen	High if dissolution profile is similar
Enteric or pH-dependent coating	Naproxen delayed until a defined pH	High for conventional delayed-release designs
Multilayer tablet	Core and outer layers, with naproxen in the core	Medium to high for tablet products
Method of treatment	Reducing NSAID-associated gastric injury while treating pain or inflammation	Depends on labeling and proposed indication
Manufacturing process	Layering, coating, compression, or pellet formation	Depends on process disclosure and proof
Formulation excipients	Specific polymers, binders, buffers, or stabilizers	Usually narrower and more design-aroundable

What is the Orange Book status of U.S. Patent 9,707,181?

The Orange Book analysis must distinguish between patent existence and Orange Book listing. A patent may be enforceable without being listed for a particular NDA, while an Orange Book listing may support a Paragraph IV certification and a 30-month stay under the Hatch-Waxman framework [2].

For a marketed esomeprazole-naproxen product, the relevant review should confirm:

whether U.S. Patent 9,707,181 is listed against the NDA;
whether it is listed as a drug-substance, drug-product, or method-of-use patent;
the listed expiration date;
whether the listing has been delisted or corrected;
whether any pediatric exclusivity period applies; and
whether an ANDA applicant has submitted a Paragraph IV certification.

The claim text alone does not establish Orange Book listing status, statutory expiration, or the existence of a Paragraph IV notice. Those facts are controlled by FDA and USPTO records, including the current Orange Book patent listing and the patent’s continuity and term-adjustment data [2, 3].

When does U.S. Patent 9,707,181 lose exclusivity?

U.S. Patent 9,707,181 issued on July 18, 2017. Its enforceable term is determined under 35 U.S.C. § 154 by the earliest effective nonprovisional filing date in the priority chain, subject to patent-term adjustment, terminal disclaimer, and any applicable patent-term extension [3].

The expiration date cannot be calculated reliably from the issue date alone. A continuation patent may expire on the same date as an earlier family member, and a terminal disclaimer may eliminate otherwise available term. For commercial diligence, the controlling sources are:

the face of the issued patent;
the USPTO Patent Center continuity data;
the patent-term adjustment statement;
any terminal disclaimer; and
the FDA Orange Book listing, if the patent is listed against an approved product.

The patent’s issue date does not create a new 20-year term.

Are Paragraph IV challenges likely for this patent?

A Paragraph IV challenge would likely focus on one or more of the following arguments:

Anticipation

An ANDA applicant could argue that an earlier fixed-dose product or published formulation disclosed:

esomeprazole in an uncoated or immediately available form;
naproxen in a pH-dependent delayed-release coating;
release of esomeprazole before naproxen; and
a single unit dosage form.

The strongest anticipation reference would need to disclose every limitation in one reference, including the pH 3.5 threshold and sequential release behavior.

Obviousness

Obviousness arguments could combine known teachings concerning:

proton-pump-inhibitor protection of NSAID therapy;
immediate-release proton-pump inhibitors;
enteric-coated naproxen;
multilayer tablets; and
pH-dependent dissolution.

The patentee would likely rely on the specific release sequence, formulation stability, manufacturing difficulty, and clinical or dissolution advantages as evidence of non-obviousness.

Written description and enablement

The claims use broad functional language across unit dosage forms, coating technologies, and release systems. An accused infringer could challenge whether the specification supports the full breadth of:

any esomeprazole form;
any naproxen coating that satisfies pH 3.5;
any unit dosage form;
any sequential release profile; and
all dose combinations within the claimed ranges.

Indefiniteness

Potential disputes could concern:

the meaning of “regardless of the pH”;
the quantitative meaning of “sequentially releases”;
the meaning of “inhibits its release”; and
the testing conditions used to determine release.

The patent specification and prosecution history would be central to these arguments.

What generic launch scenarios exist?

Scenario	Product design	Patent exposure
Same-strength tablet	500 mg naproxen and 20 mg esomeprazole	Highest exposure to claims 1-4
Different in-range strength	250 mg naproxen and 20 mg esomeprazole	Still potentially within claims 2-4
Multilayer tablet	Naproxen core and esomeprazole outer layer	Direct exposure to claims 5-7
Capsule with pellets	Uncoated esomeprazole plus coated naproxen pellets	Potential claim 1 exposure
Separate co-packaged products	Two physically separate dosage units	Reduced exposure to the unit-dosage-form limitation
Simultaneous-release formulation	Both actives released together	Potential defense to sequential-release limitation
Naproxen released below pH 3.5	No required threshold behavior	Potential defense, subject to actual testing
Esomeprazole fully enteric-coated	No uncoated portion	Potential defense to claim 1

An ANDA applicant cannot avoid infringement solely by using a different brand name, tablet color, compression force, or conventional excipient. The decisive evidence is the final product’s structure and dissolution profile.

What is the patent strength of U.S. Patent 9,707,181?

The patent has a mixed strength profile.

Factor	Assessment
Product relevance	High for products replicating the esomeprazole-before-naproxen design
Claim breadth	Broad in claim 1; narrower in claims 5-7
Design-around potential	Moderate, particularly through separate dosage units or different release ordering
Proof burden	Significant because infringement may depend on dissolution testing
Obviousness exposure	Material because the components and therapeutic rationale were known
Commercial relevance	High for fixed-dose esomeprazole-naproxen products
Manufacturing barrier	Moderate; layered and coated systems can be technically difficult to reproduce
Biosimilar relevance	None; this is a small-molecule drug patent
ANDA relevance	High if the patent is listed for the reference product

The most valuable limitation is the required release sequence. The most vulnerable limitations may be the broad functional phrases concerning pH-independent esomeprazole release and sequential release without a quantitative threshold.

Does the patent create biosimilar risk?

No. Esomeprazole and naproxen are small-molecule active ingredients. The relevant competitive pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Public Health Service Act [2].

The commercial threat consists of:

generic fixed-dose combination tablets;
generic modified-release tablets;
alternative multiparticulate dosage forms; and
separate generic products used in combination.

A generic applicant would evaluate Orange Book listings, Paragraph IV exposure, bioequivalence requirements, and formulation patents. Biosimilar interchangeability and biologic reference-product exclusivity do not apply.

What litigation and settlement issues matter?

The key litigation questions are:

whether the patent is listed against the relevant NDA;
whether an ANDA applicant filed a Paragraph IV certification;
whether the NDA holder filed suit within 45 days;
whether a 30-month stay was triggered;
whether the parties entered a settlement or license;
whether the settlement permits an agreed generic launch date; and
whether any authorized generic or licensed generic arrangement exists.

A settlement may resolve patent litigation without invalidating the patent. The commercial effect depends on the agreed launch date, supply rights, royalty terms, and restrictions on alternative formulations. The patent number alone does not establish that litigation or settlement occurred.

Key Takeaways

U.S. Patent 9,707,181 targets a single unit dosage form containing esomeprazole and naproxen.
Claim 1 requires esomeprazole release before naproxen release.
Naproxen must be protected by a coating that inhibits release below pH 3.5.
The patent is not limited to a particular tablet shape or coating polymer.
Claims 5-7 specifically target multilayer tablets with naproxen in the core and no naproxen in the outer layers.
Dose claims cover 200-600 mg naproxen and 5-100 mg esomeprazole.
The patent is relevant to generic fixed-dose combination products, not biosimilar products.
Orange Book listing, expiration, Paragraph IV activity, litigation, and settlement status require confirmation from current FDA and USPTO records.
The primary design-around strategies involve separate dosage units, altered release order, simultaneous release, or a naproxen release profile that does not satisfy the pH 3.5 limitation.

FAQs

Can a generic use the same 500 mg naproxen and 20 mg esomeprazole strengths?

Yes, but the strength change alone would not avoid the patent. A 500 mg/20 mg product would fall within the numerical ranges of claims 2-4 if it also satisfies the structural and release limitations of claim 1.

Would an enteric-coated esomeprazole formulation avoid claim 1?

Not necessarily. Claim 1 requires that at least a portion of esomeprazole not be surrounded by an enteric coating. A product containing both enteric-coated and uncoated esomeprazole could still satisfy that limitation.

Does a capsule automatically avoid the patent?

No. Claim 1 is directed to a unit dosage form and is not limited to tablets. A capsule containing uncoated esomeprazole and suitably coated naproxen could present infringement risk.

Is a pH 3.5 threshold the same as a conventional enteric coating?

Not automatically. The claim is based on release behavior. A coating may be covered if it inhibits naproxen release below pH 3.5, even if it uses a nontraditional polymer or coating process.

Can a product avoid infringement by releasing both ingredients at the same time?

Potentially. Simultaneous release could provide a defense to the “sequentially releases” limitation, but the conclusion would depend on validated dissolution testing and the applicable construction of “sequentially.”

References

U.S. Food and Drug Administration. (2010). Vimovo (naproxen and esomeprazole magnesium) delayed-release tablets: Prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
United States Patent and Trademark Office. (2017). U.S. Patent No. 9,707,181.
35 U.S.C. § 154. Patent term.
Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 355. New drug applications and abbreviated new drug applications.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1411900	⤷ Start Trial	C300481	Netherlands	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	91858	Luxembourg	⤷ Start Trial
European Patent Office	1411900	⤷ Start Trial	1190013-1	Sweden	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 9,707,181

Summary for Patent: 9,707,181